← Back to scans

Will Trump make IVF free? — Before 2029

KXFREEIVF-29 · Health · 2026-05-06
12%
Agent
17%
Market Price
-5.0%
Edge
62%
Confidence
Volume: 34,133
Spread: 2.0c
Days to resolution: 989
Markets in event: 1
Final Rationale
My independent 9.7% estimate was anchored on strong negative signals: the Aug 2025 explicit no-mandate statement, the Oct 2025 voluntary-only TrumpRx discount pivot, the missed May 2025 EO deadline, and NDAA IVF coverage being stripped in Dec 2025. I PARTIALLY ACCEPT the critique on resolution ambiguity and pathway combination — 'at least one IVF cycle' free for a narrow population (e.g., expanded VA/military benefit or a Medicaid pilot) is a real tail pathway my weighted-average combination underweighted, so I adjust upward by ~2-3pp. I REJECT the implication that I should fully match the market, since the market's 15% with HIGH liquidity reflects the same evidence base plus tail scenarios, and 989 days of pronatalist pressure plus pre-2028-election political stunts justify some but not all of the premium. Settling at 12% acknowledges the OR-logic across narrow pathways while preserving the strong base rate and revealed-preference evidence that the administration has chosen a discount-not-free path.
Price vs. prediction
How the market moved after the agent's call. Solid blue line is the actual market price; dashed line is the agent's static forecast at $t{=}0$.
$n = 58$ follow-ups
Re-scan Context
This market has been scanned before. Previous predictions:
DatePredictedMarket PriceConfidence
2026-04-29 14% 16% 50%
2026-04-03 10% 16% 50%
1. Planner Opus · Fermi decomposition + tool plan
Tools chosen: kalshi_data article_search web_search congress_bills kalshi_orderbook
Sub-questions (Fermi decomposition)
  1. Will Trump sign executive or legislative action specifically mandating free IVF coverage before January 20, 2029? (w=0.45)
  2. Has Trump taken any concrete steps (executive orders, formal proposals, or legislative pushes) toward making IVF free as of mid-2026? (w=0.30)
  3. Will Congress pass IVF-related legislation that eliminates cost for at least one cycle before January 20, 2029? (w=0.25)
Planner reasoning
This question asks whether Trump will eliminate cost for at least one IVF cycle — a high bar requiring affirmative presidential action. Key causal factors: (1) Trump has rhetorically supported IVF access since the 2024 campaign and issued a February 2025 executive order directing agencies to develop IVF access policy, but rhetoric and direction-setting fall short of actually making IVF 'free'; (2) 'free' requires either federal subsidy programs, insurance mandate with no cost-sharing, or direct government payment — all of which face fiscal and political headwinds; (3) The Republican base has mixed views on fertility treatment given IVF's intersection with abortion politics; (4) With 989 days remaining (until Jan 20, 2029), the remaining Trump term provides roughly 2.5 years. Timeline: for YES, Trump would need to either (a) issue a more aggressive EO creating a federal subsidy program, or (b) sign legislation passed by Congress. Option (b) requires legislative calendar alignment and bipartisan support that has historically been elusive. Reference class: Trump issued a 'direction to study' EO but implementing actual zero-cost IVF would be unprecedented federal health benefit expansion. Most presidential campaign promises on health benefit expansion fail to fully materialize. The distinction between 'supporting IVF access' and 'making IVF free' is critical — nearly all policy activity so far falls in the former category. Base rate for this specific commitment being fully implemented: very low, perhaps 5-12%.
2. Research Parallel tool calls · legacy v2
ToolStatusTimeItemsSummary
kalshi_data OK 1.9s -
article_search OK 0.8s -
web_search OK 66.2s -
congress_bills OK 0.6s -
kalshi_orderbook OK 0.1s -
3. Evidence Synthesis Sonnet · 11 items · legacy v2
#StrengthCredibilityDirectionSourceClaimPriced In
1 STRONG 82 ↓ DOWN article_search As of August 2025, the White House has no plan to mandate IVF care despite Trump's campaign pledge, with two people with knowledge of internal discussions confirming this to reporters. Yes
2 STRONG 88 ↓ DOWN article_search October 2025 White House IVF announcement explicitly stated the government will NOT offer subsidies to employers or require coverage — only voluntary guidance for employers to offer fertility benefits. Yes
3 STRONG 85 ↓ DOWN web_search The February 2025 executive order only directed policy recommendations within 90 days; it did not mandate insurance coverage, create subsidies, or fulfill the 'free IVF' campaign promise. Yes
4 MODERATE 65 ↓ DOWN kalshi_data Kalshi prediction market prices the 'Trump makes IVF free before 2029' question at 15%, down 2% over both 7 and 30 days, suggesting declining market confidence. Yes
5 STRONG 85 ↓ DOWN article_search Trump signed a February 2025 executive order on IVF, but the May 2025 deadline for policy recommendations passed without substantive White House action, per CBS News reporting. Yes
6 STRONG 87 ↑ UP article_search On October 16, 2025, Trump announced a drug pricing deal with EMD Serono to reduce costs of three IVF medications by ~73-84% via TrumpRx.gov, representing the most concrete policy action to date. Yes
7 MODERATE 78 ↓ DOWN web_search TrumpRx.gov launched in February 2026 with discounted fertility drugs, but savings apply only to a narrow subset of IVF medications representing a fraction of total cycle costs ($2,200 savings vs. $25,000+ total cycle cost). Yes
8 STRONG 87 ↓ DOWN web_search All concrete Trump administration steps toward IVF access fall short of making IVF 'free': actions include voluntary employer benefit guidance and drug discount deals, not mandates or direct federal payment programs. Yes
9 MODERATE 75 ↓ DOWN article_search State-level IVF legislation is advancing (Tennessee, Virginia, California, Georgia) but no federal legislation mandating zero-cost IVF coverage has been identified in the research data. Yes
10 STRONG 82 ↓ DOWN article_search The White House explicitly stated it has no plan for a federal insurance mandate for IVF coverage, removing the most likely legislative vehicle for zero-cost IVF. Yes
11 MODERATE 70 NEUTRAL kalshi_orderbook Kalshi orderbook for this market shows HIGH liquidity with 25,522 depth, indicating a well-traded market whose current 15% price reflects informed participant consensus. Yes
Information Gaps
  • No data on any Congressional IVF legislation introduced or advancing in 2026 that could establish zero-cost coverage
  • No information on whether TrumpRx.gov's IVF drug discounts have been expanded or whether additional drug manufacturers have joined since February 2026
  • No data on whether the 'Big Beautiful Bill' or any omnibus legislation being discussed in 2026 includes IVF provisions
  • No evidence about whether DOD/VA military benefit expansions for IVF (which have been discussed separately) might create a pathway to broader coverage
  • No information on Medicaid expansion to cover IVF, which could theoretically be pursued via executive action
  • No data on pronatalist policy discussions within the White House (e.g., Vance's pronatalism agenda) that might elevate IVF funding priority
Key Uncertainties
  • Whether the administration might dramatically escalate IVF policy in 2027-2028 as part of a pronatalist agenda push ahead of midterms
  • Whether 'free' could be satisfied by a narrow program (e.g., covering one cycle for military families or Medicaid recipients) vs. universal coverage
  • The resolution criteria ambiguity: whether a deep discount (e.g., 90%+ reduction via TrumpRx) could be interpreted as 'eliminating the cost' under the question's terms
  • Whether fiscal pressures from DOGE-era budget cuts make new federal healthcare spending programs politically impossible
  • Republican internal tensions on IVF given evangelical opposition to embryo destruction, which constrains the legislative pathway
Market Context
Price: 0.15 · 7d: -0.02 · 30d: -0.02
Volume: MODERATE — 145 avg daily contracts, sufficient for price discovery · Depth: HIGH — 25,522 depth units
Reliability: MEDIUM-HIGH — high liquidity and depth suggest informed market; price has been declining and currently sits near the lower end of its historical range (9%-39%), reflecting accumulated evidence that the administration's actions fall far short of making IVF free
4. Independent Forecaster Opus · No market price · legacy v2 Did NOT see market price
Independent estimate: 10% (65% confidence)
base rate
10%
62% conf
evidence driven
9%
70% conf
contrarian
10%
62% conf
Spread
1pp
Low disagreement
sq1: Will Trump sign executive or legislative action specifically mandating free IVF coverage before January 20, 2029?
6%
Base rate for major presidential health benefit expansion via mandate in a single term is very low (<10%). Multiple strong signals push DOWN: White House explicitly stated no mandate plan (Aug 2025), October 2025 announcement was voluntary-only guidance, Feb 2025 EO was study-only with missed deadline. With ~2.5 years remaining, a pivot to mandate would require reversing established policy direction. Slight UP adjustment for pronatalist agenda potentially escalating. Final: 6%.
sq2: Has Trump taken any concrete steps toward making IVF free as of mid-2026?
20%
This sub-question is about whether STEPS toward 'free IVF' have been taken. Trump has taken steps toward IVF access (EO, drug discounts via TrumpRx) but these fall short of 'free.' The TrumpRx discounts (~$2,200 savings on $25K+ cycle) reduce but don't eliminate cost. If interpreted strictly as steps toward truly free IVF, probability is low (~20%). The drug discount could be liberally interpreted as a 'step toward' but doesn't make any cycle free. Final: 20%.
sq3: Will Congress pass IVF-related legislation that eliminates cost for at least one cycle before January 20, 2029?
5%
Base rate for major new federal health entitlements passing Congress in any given 3-year window is very low (<5%). NDAA IVF coverage was stripped Dec 2025, signaling Republican caucus opposition. Evangelical opposition to embryo destruction blocks Republican unified support. No federal zero-cost IVF legislation identified. Democrats lack majority. Final: 5%.
Show full reasoning trace
base rate: Presidential campaign promises for major new health benefits rarely fully materialize within a term (<15% historical rate). 'Free IVF' specifically has no precedent at federal level. Reference class: campaign-promised health expansions like Obama's public option, Trump's previous insurance promises — most failed.
evidence updates: Strong DOWN: Aug 2025 explicit no-mandate statement, Oct 2025 voluntary-only announcement, Feb 2025 EO was study-only with missed May deadline, NDAA IVF coverage stripped, White House pivoted to drug discounts (limited savings). Slight UP: pronatalist agenda interest, ~2.5 years remaining provides time for policy shifts, narrow programs (military/Medicaid) could technically satisfy resolution.
combination method: Weighted average across three pathways yielded ~10%. Adjusted slightly considering possibility of narrow program satisfying 'at least one IVF cycle' free criterion.
final: Strong evidence the administration has chosen a voluntary/discount path rather than free IVF. The probability that Trump pivots to actually eliminating cost of an IVF cycle by Jan 2029 is low but non-negligible given remaining time and pronatalist political incentives. Final estimate: 10%.
ensemble: {'ensemble_count': 3, 'perspectives': {'base_rate': {'p_yes': 0.1, 'confidence': 0.62}, 'evidence_driven': {'p_yes': 0.09, 'confidence': 0.7}, 'contrarian': {'p_yes': 0.1, 'confidence': 0.62}}, 'spread': 0.01, 'individual_p_yes': {'base_rate': 0.1, 'evidence_driven': 0.09, 'contrarian': 0.1}}
5. Devil's Advocate Sonnet · legacy v2 Market price revealed
Reasoning Flaw Missing Info
Challenges
  1. Resolution criteria ambiguity is underweighted: 'Make IVF free' could resolve YES via narrow pathways (e.g., expanded military/VA IVF benefits, a Medicaid demonstration, or a single-cycle pilot program) that are far more achievable than a universal mandate. The forecaster acknowledges this but doesn't seem to incorporate it heavily into the final number — sq1 at 6% and sq3 at 5% may be too low if 'at least one cycle free for some population' suffices.
  2. The sub-questions are not mutually exclusive pathways and the 'weighted average' combination method is not clearly justified. If the question resolves YES on ANY pathway (executive action OR legislation OR narrow program), the correct combination is closer to 1 - product of (1-p_i), which would push the estimate higher than a simple average.
  3. 989 days remain — a substantial window. The forecaster correctly notes time remaining but then heavily weights current administration posture (Aug/Oct 2025 statements) as if it were stable for 2.5+ more years. Pronatalist pressure, midterm dynamics, and Vance positioning for 2028 all create plausible pivot scenarios that aren't quantified.
  4. The Kalshi market at 15% with HIGH liquidity and 25k+ depth is informed by the same negative evidence the forecaster cites, yet still settles meaningfully above the forecast. This suggests the market is pricing in tail pathways (narrow programs, last-year political stunts) that the forecaster may be underweighting.
Suggested adjustment: +3pp
Modest upward adjustment warranted because (1) the question may resolve on narrow pathways (military/VA/Medicaid pilot covering 'at least one cycle') that the forecaster acknowledges but underweights, and (2) the sub-question combination appears to use averaging rather than OR-logic across independent pathways, which mechanically understates the probability. This is a reasoning issue, not market conformity — though notably it brings the estimate closer to the liquid market.
Market comparison: Forecaster: 9.7%, Market: 15.0%. The 5.3pp divergence is modest. The market has been declining toward the forecaster's range, suggesting accumulated negative evidence is being priced in. However, the market's persistent premium likely reflects narrow-pathway tail scenarios and the long 989-day horizon. Divergence is partially justified by strong negative evidence but the forecaster may be slightly overconfident given resolution ambiguity.
6. Aggregator Opus · final calibrated forecast
12% (62% confidence)
My independent 9.7% estimate was anchored on strong negative signals: the Aug 2025 explicit no-mandate statement, the Oct 2025 voluntary-only TrumpRx discount pivot, the missed May 2025 EO deadline, and NDAA IVF coverage being stripped in Dec 2025. I PARTIALLY ACCEPT the critique on resolution ambiguity and pathway combination — 'at least one IVF cycle' free for a narrow population (e.g., expanded VA/military benefit or a Medicaid pilot) is a real tail pathway my weighted-average combination underweighted, so I adjust upward by ~2-3pp. I REJECT the implication that I should fully match the market, since the market's 15% with HIGH liquidity reflects the same evidence base plus tail scenarios, and 989 days of pronatalist pressure plus pre-2028-election political stunts justify some but not all of the premium. Settling at 12% acknowledges the OR-logic across narrow pathways while preserving the strong base rate and revealed-preference evidence that the administration has chosen a discount-not-free path.
7. Entry Decision Opus Trader
Side
NO
Position Size
$600
Contracts
706
Trader Confidence
62%
Trade Rationale
Edge is -5.0% (forecast 12% vs market 17%), right at the minimum threshold for trading. The forecaster's 62% confidence is moderate, and the Devil's Advocate flagged both a reasoning_flaw and missing_info, suggesting a +3pp adjustment — meaning the true edge could be closer to -2pp, which would be a skip. The fundamental evidence (Aug 2025 no-mandate statement, Oct 2025 voluntary TrumpRx pivot, NDAA stripping IVF) strongly supports the NO side, but with 989 days to resolution there's significant tail risk from pronatalist political stunts pre-2028. Given the marginal edge and critic concerns, I'll take a small NO position rather than skip entirely.
Allocation Logic
Sizing at $600 — near the floor — because the edge is at the minimum threshold (5%), the critic flagged real concerns warranting a +3pp adjustment that would shrink the edge further, and the very long 989-day horizon adds uncertainty. Worth a small bet given the strong fundamental evidence on the NO side, but not more.
Entry price: $0.85
Current: $0.86
Status: OPEN
P&L: $7.06